ライフサイエンスコーパス: antitumor activity

1 exhibits superior selectivity, potency, and antitumor activity.

2 ly on significant in vivo expansion to exert antitumor activity.

3 r is a novel and safe therapeutic with broad antitumor activity.

4 /FGFR interaction and endowed with promising antitumor activity.

5 Selenosemicarbazones show marked antitumor activity.

6 gin, a cytotoxic natural product with potent antitumor activity.

7 s) were enrolled and assessed for safety and antitumor activity.

8 ygen species (ROS) that substantially impair antitumor activity.

9 /TRAIL achieved markedly better exposure and antitumor activity.

10 which promoted tumor T cell infiltration and antitumor activity.

11 and 1 (PD-L1) and PD-1 have shown impressive antitumor activity.

12 ors of the innate immune system, with marked antitumor activity.

13 rols CD8(+) T memory precursor formation and antitumor activity.

14 ngender a costimulatory signal that augments antitumor activity.

15 SA50 rate with orteronel-prednisone indicate antitumor activity.

16 essibility and immune effector cell mediated antitumor activity.

17 an anti-class II MHC antibody abrogated its antitumor activity.

18 l source that exhibits potent antiangiogenic antitumor activity.

19 s been significantly hindered due to the low antitumor activity.

20 tabolism, acceptable toxicity, and promising antitumor activity.

21 , where the loss of CAT2 results in enhanced antitumor activity.

22 ocycline, a synthetic tetracycline, displays antitumor activity.

23 f-antigen-specific TCRs and ensure selective antitumor activity.

24 atumoral exposure of SN-38 but with superior antitumor activity.

25 1 antibody, confirming a role for T cells in antitumor activity.

26 of AP-1, induced by IFN) that display potent antitumor activity.

27 atural killer cells, to the tumor stroma for antitumor activity.

28 l threshold of 120 nmol/L as determinant for antitumor activity.

29 oved colloidal stability and greater in vivo antitumor activity.

30 e, compounds with known antibacterial and/or antitumor activity.

31 atio at the tumor site, and triggered potent antitumor activity.

32 ularly in a specific subset, promoting their antitumor activity.

33 lar endothelial cells eliminated most of the antitumor activity.

34 ombine with immuno-oncology drugs to enhance antitumor activity.

35 as a manageable safety profile and promising antitumor activity.

36 CAR) may reduce the side effects and augment antitumor activity.

37 in-like (KIR) receptors and interrupts their antitumor activity.

38 ts of the PLN carrier, but also had moderate antitumor activity.

39 sessed for toxicities, pharmacokinetics, and antitumor activity.

40 potent microtubule depolymerizing agent with antitumor activity.

41 ng cancer cells, but significantly different antitumor activities.

42 Loss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-c

43 sults provide a proof of concept of systemic antitumor activity after intratumoral CD40 triggering wi

44 to a pyrophosphate moiety, exhibit excellent antitumor activities against a variety of cancers.

45 oduct and its structural analogues exhibited antitumor activities against several human cancer cell l

46 ed for concurrent PLK1 inhibition to improve antitumor activity against a therapy-resistant cell comp

47 f the IL-2 cytokine family, possesses potent antitumor activity against a variety of cancers not expr

48 hromene designated DHM25 that exerted potent antitumor activity against breast tumor cell lines.

49 mel(TLR5L)) displayed a relative increase in antitumor activity against established tumors, compared

50 mouse xenografts revealed that 6OTD exhibits antitumor activity against glioblastoma.

51 and metabolic stability and 39 times higher antitumor activity against hormone-resistant prostate ca

52 nsus androgen response element half-site has antitumor activity against hormone-sensitive prostate ca

53 r, these data indicate that IL-21 has potent antitumor activity against MCL cells via direct cytotoxi

54 nstrated a safety therapy profile with broad antitumor activity against solid and hematological malig

55 hich suggests that these agents have similar antitumor activity among patients with advanced NETs.

56 to facilitate T cell proliferation, enhance antitumor activities and promote T cell-dependent antibo

57 fies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profil

58 embrolizumab exhibited clinically meaningful antitumor activity and an acceptable safety profile in r

59 may serve as a novel platform to improve the antitumor activity and clinical efficacy of therapeutic

60 cervical cancer, pembrolizumab demonstrated antitumor activity and exhibited a safety profile consis

61 ing circuitry that regulates ERbeta-specific antitumor activity and has potential as both a prognosti

62 LMB-T18 has high cytotoxic and antitumor activity and is very resistant to thermal dena

63 Despite the greater antitumor activity and lower toxicity obtained with diff

64 olarized macrophages with antiangiogenic and antitumor activity and M2-type polarized macrophages, wh

65 not the unique arbiters of cytotoxicity and antitumor activity and meaningful antitumor profiles can

66 Here, we study the antitumor activity and mechanism of action of a nonrepli

67 We studied the antitumor activity and mechanism of action of a novel, i

68 These studies indicate that everolimus has antitumor activity and provide proof-of-concept that tar

69 ity characteristics can lead to improved ADC antitumor activity and reduced neutropenia.

70 4 and 7, respectively, which showed enhanced antitumor activity and substantially improved the metabo

71 In this study, the antitumor activity and the underlying mechanisms of aila

72 ) cytotoxic T lymphocytes (CTLs) have potent antitumor activity and therefore are leading candidates

73 mily member specificity profiles for optimal antitumor activity and tolerability.

74 rapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising

75 ondary objectives included pharmacokinetics, antitumor activity, and pharmacodynamics.

76 ively localized to the tumor site had potent antitumor activity, and repeat injections significantly

77 NK cell memory-like properties, evidence for antitumor activity, and the challenges and opportunities

78 wever, the critical substrates mediating its antitumor activity are not fully defined.

79 The biochemical mechanisms underlying their antitumor activity are unknown.

80 mRNA (TriMixDC-MEL) are immunogenic and have antitumor activity as a monotherapy in patients with pre

81 Blinatumomab has shown potent antitumor activity as a single agent, particularly for a

82 notoxin based on HN3 (HN3-PE38) has superior antitumor activity as compared with YP7 (YP7-PE38) both

83 BET proteins in tumors and exhibited strong antitumor activities at well-tolerated dosing schedules.

84 l is as efficacious as melphalan, displaying antitumor activity at doses corresponding to only a frac

85 mbining decitabine and navitoclax heightened antitumor activity beyond administration of either compo

86 n in K27M tumor cells and demonstrate potent antitumor activity both in vitro against K27M cells and

87 S and MEK leads to more robust apoptosis and antitumor activity both in vitro and in vivo than effect

88 id-Pt-Cl (LPC) NPs, which showed significant antitumor activity both in vitro and in vivo.

89 peutics metformin and phenformin, have shown antitumor activity both in vitro and in vivo.

90 t, Ctn(15-34), retains the antimicrobial and antitumor activities but is less toxic to healthy cells

91 nscriptionally active ERbeta mutant retained antitumor activity but circumvented control by upstream

92 ent protein kinase inhibitors with promising antitumor activity but suboptimal aqueous solubility, co

93 ORC1), exhibit immunosuppressive and limited antitumor activity, but sometimes activate survival path

94 ds to HSP90 and/or hnRNP A2/B1 and initiates antitumor activities by affecting Slug- and AKT-mediated

95 yrin micelles (SN-NPM) enhanced the in vitro antitumor activity by 78 and 350 times over single treat

96 mulating factor (G-CSF) enhanced RT-mediated antitumor activity by activating RT-Ns.

97 presence of cellular thiols, LNM exerts its antitumor activity by an episulfonium ion-mediated DNA a

98 es capable of activating p38 MAPK lose their antitumor activity by deleting B7-H1(+) tumor-reactive C

99 phorylation of PTPN12 by CDK2 discharged its antitumor activity by down-regulation of its inhibitory

100 Remarkable antitumor activity by means of objective radiologic resp

101 trate that SIRPalpha blockade induces potent antitumor activity by targeting multiple myeloid cell su

102 these results demonstrate that JA exerts its antitumor activity by targeting SF3B1 and SF3B3 in addit

103 1,2-dithiolane moiety is essential for LNM's antitumor activity, by virtue of its ability to generate

104 une checkpoint inhibitors has shown enhanced antitumor activity compared with monotherapy in tumor ty

105 g CAd-VECPDL1 with HER2.CAR T cells enhanced antitumor activity compared with treatment with either H

106 to generate more stable compounds possessing antitumor activity consistent with on-target inhibition

107 and upon activation while maintaining their antitumor activity despite high H2O2 levels.

108 in human cells, suggests that the selective antitumor activity displayed by OPA may be due to altere

109 olate intracellular retention and antifolate antitumor activity, displays a pronounced species differ

110 This phase II trial assessed the antitumor activity, dose-response relationship, and safe

111 Here, we report potent antitumor activity for a novel fusion cytokine generated

112 ne was limited despite a substantial initial antitumor activity found in the primary tumor setting.

113 The secondary end points included antitumor activity, gpNMB expression, and immunogenicity

114 es to selectively inhibit NF-kappaB to exert antitumor activity have been elusive.

115 r range associated with a remarkable in vivo antitumor activity, highly competitive with the most pot

116 DNAM-1 display abnormal T cell responses and antitumor activity; however, the mechanism involved is u

117 lead drug candidates 9a and 18 demonstrated antitumor activities in animal models.

118 related pathways, induces apoptosis, and has antitumor activity in a broad range of both hematologica

119 Furthermore, PF-06463922 demonstrated antitumor activity in a genetically engineered mouse mod

120 Compound 3g had in vivo antitumor activity in a murine model comparable to the a

121 iquitinases of the 19S proteasome that shows antitumor activity in a number of tumor models, includin

122 tate-specific antigen response rates suggest antitumor activity in a patient subset.

123 imab, 2B8T2M exhibits significantly stronger antitumor activity in a xenograft SCID mouse model and d

124 1F5hIgG1 had good antitumor activity in all tumor models tested.

125 D9 bromodomain cellular function and display antitumor activity in an AML xenograft model.

126 Notably, EGF816 also demonstrated antitumor activity in an exon 20 insertion mutant model.

127 pecific chimeric antigen receptor (CAR) have antitumor activity in B cell malignancies; however, iden

128 able pharmacokinetic properties, and in vivo antitumor activity in both the SJSA-1 osteosarcoma xenog

129 Nivolumab was well tolerated and exhibited antitumor activity in extensively pretreated patients wi

130 HER2-TDB exhibited potent antitumor activity in four preclinical model systems, in

131 ylase (HDAC) inhibition has shown remarkable antitumor activity in hematological malignancies, it has

132 f MM-302 and trastuzumab induced synergistic antitumor activity in HER2-overexpressing xenograft mode

133 ispecific T-cell engagers (BITEs) have shown antitumor activity in humans for CD19-positive malignanc

134 ADCs had greater antitumor activity in immunocompetent versus immunodefic

135 Noticeably, XWL-1-48 exerted potent antitumor activity in in vitro and in vivo human hepatoc

136 ently induces apoptosis leading to sustained antitumor activity in in vivo xenograft models of both s

137 ion of MK-1775 and Ex527 induces cooperative antitumor activity in lung cancer xenograft model in viv

138 ine whether the MMP12 CTD contributes to its antitumor activity in lung cancer.

139 mmune checkpoint blockade results in durable antitumor activity in many advanced malignancies.

140 Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including com

141 DM1 conjugate SIP(F8)-SS-DM1 mediated potent antitumor activity in mice bearing DM1-sensitive F9 tumo

142 STING activator cGAMP possesses significant antitumor activity in mice by triggering the STING-depen

143 er, the Her2 x CD3 BsAb shows potent in vivo antitumor activity in mouse Her2(2+) and Her2(1+) xenogr

144 rains of measles virus (MV) have significant antitumor activity in mouse xenograft models of ovarian

145 temsirolimus was tolerable and demonstrated antitumor activity in multiple tumor types, warranting f

146 c9A(+) dendritic cells (DC) displayed strong antitumor activity in murine melanoma, breast carcinoma,

147 ls have already shown clinically significant antitumor activity in neuroblastoma, chronic lymphocytic

148 ble safety profile and exhibited substantial antitumor activity in newly diagnosed patients with CD30

149 Importantly, TF-011-MMAE showed excellent antitumor activity in patient-derived xenograft (PDX) mo

150 ell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma.

151 an acceptable side-effect profile and showed antitumor activity in patients with advanced non-small-c

152 ed a manageable safety profile and promising antitumor activity in patients with metastatic RCC.

153 Single-agent volasertib showed antitumor activity in patients with ovarian cancer.

154 active selective PI3Kdelta inhibitor, showed antitumor activity in patients with previously treated i

155 In summary, brentuximab vedotin showed antitumor activity in patients with relapsed PTCL partic

156 -cell lymphoma (TCL) cell lines and assessed antitumor activity in patients with relapsed/refractory

157 ulation of irinotecan can safely improve its antitumor activity in preclinical models by enhancing ac

158 s inhibitor of Wee1 kinase with single-agent antitumor activity in preclinical models.

159 Alisertib has antitumor activity in PTCL, including heavily pretreated

160 ble and manageable safety profile and showed antitumor activity in several tumor types, including FGF

161 PD-1 blockade has produced significant antitumor activity in solid tumors, and similar evidence

162 ive cancer because AKT inhibition has potent antitumor activity in the DLC1-positive transgenic cance

163 Orally administered, 31 achieves significant antitumor activity in the MV4;11 leukemia and MDA-MB-231

164 An antagonistic anti-CCR4 antibody had antitumor activity in the RENCA mouse model of RCC.

165 kable pharmacokinetic properties and in vivo antitumor activity in the SJSA-1 osteosarcoma xenograft

166 Compound 4 also shows excellent antitumor activity in the SJSA-1 osteosarcoma xenograft

167 Compound 4 also shows excellent antitumor activity in the SJSA-1 osteosarcoma xenograft

168 as compared with dabrafenib alone, enhanced antitumor activity in this population of patients.

169 binant protein anti-EGFR-iRGD also exhibited antitumor activity in tumor cell lines, multicellular sp

170 In vivo, PF-06463922 showed marked antitumor activity in tumor models expressing FIG-ROS1,

171 hway, which results in T-cell activation and antitumor activity in tumor models.

172 ed that (19)F-FCP, like carboplatin, retains antitumor activity in various cell lines.

173 checkpoint were shown to display impressive antitumor activity in various solid or hematological mal

174 ceptor (TNFR)-related protein (GITR) elicits antitumor activity in various tumor models; however, the

175 diols and their keto derivatives showed high antitumor activity in vitro against Hek293, Jurkat, K562

176 e thiosemicarbazone (ApT) series show potent antitumor activity in vitro and in vivo, we synthesized

177 Apo2L/TRAIL with AMG 655 leads to increased antitumor activity in vitro and in vivo.

178 kin-24 (mda-7/IL-24) promotes broad-spectrum antitumor activity in vitro, in vivo in preclinical anim

179 ed mutations and had potent antifibrotic and antitumor activity in vivo in mouse models of PMF.

180 human colon cancer cells, but also improved antitumor activity in vivo.

181 Vivo-Morpholino directed at mouse Gls had no antitumor activity in vivo.

182 ike functions that may be exploited to boost antitumor activity in vivo.

183 atenin signaling in HCC cells and had potent antitumor activity in vivo.

184 The most active agent, 3c, was evaluated for antitumor activity in vivo.

185 on results in potent, dose-dependent in vivo antitumor activity in xenograft models.

186 anoma B16F10 xenograft model to validate its antitumor activity, in comparison with reference ABT-751

187 sistant tumors, PS-1001 resulted in enhanced antitumor activity, increased infiltration of macrophage

188 in alone did not yield survivin knockdown or antitumor activity, indicating the in vivo effectiveness

189 t a long-lived phenotype exhibiting improved antitumor activities into T-cells by transfecting them w

190 ll killing in clinic, but the basis of their antitumor activity is not fully understood.

191 vious studies demonstrated that IL-12-driven antitumor activity is short-circuited by a rapid switch

192 that the molecular mechanism underlying its antitumor activity is unrelated to its effect on coagula

193 drugs with antiviral, immunosuppressive and antitumor activities, its physiological mechanisms of re

194 e, we examine the hypothesis that the TIMP-2 antitumor activity may involve regulation of the SP in h

195 f cereblon modulator 3 (CC-885), with potent antitumor activity mediated through the degradation of G

196 The encouraging antitumor activity observed in patients with TP53-mutate

197 ented the ability of MEDI5117 to enhance the antitumor activities of chemotherapy or gefitinib in com

198 y influence the development, maturation, and antitumor activities of immune cells.

199 irect protein target for the teratogenic and antitumor activities of immunomodulatory drugs such as t

200 Here we review antitumor activities of innate immune cells, mechanisms

201 ction of NO and CCL2, were essential for the antitumor activity of 3M-052.

202 in a mouse syngenic model demonstrated high antitumor activity of 4o, which significantly reduced th

203 Furthermore, cGAMP improved the antitumor activity of 5-FU, and clearly reduced the toxi

204 udy, we defined parameters that maximize the antitumor activity of a nanoliposomal formulation of iri

205 DX3 in sarcoma cells, and to investigate the antitumor activity of a novel small molecule DDX3 inhibi

206 vaccine treatments consistently negated the antitumor activity of a selective BRAF inhibitor in tumo

207 TLA-4) checkpoint blockade might enhance the antitumor activity of adoptively transferred CTLs.

208 eveals that the ICOS pathway potentiates the antitumor activity of adoptively transferred Tc17 cells.

209 lly deficient in the ICOS ligand reduced the antitumor activity of adoptively transferred Tc17 cells.

210 ) IIB is an absolute requirement for in vivo antitumor activity of agonistic mouse anti-CD40 monoclon

211 evelop a combination strategy to enhance the antitumor activity of ALK inhibitor monotherapy in human

212 e I study sought to determine the safety and antitumor activity of AM0010.

213 L-15Ralpha/IL-15 fusion protein RLI enhances antitumor activity of anti-PD-1 treatment and is a promi

214 Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti-progr

215 e cells with IL-7 and IL-15 produced greater antitumor activity of CAR-T cells mediated by increased

216 xpression in lymphoma cells and improved the antitumor activity of CD19-CART in vivo.

217 The costimulation and antitumor activity of CD27 agonistic Abs have been well

218 The antitumor activity of CD4(+) T cells is increasingly ack

219 proliferation, cytokine production, and the antitumor activity of CD8(+) T cells upon antigenic stim

220 In this study, we examined the antitumor activity of CMLD-2, a small-molecule inhibitor

221 nt intratumoral retention that increased the antitumor activity of coadministered temozolomide (TMZ).

222 Despite the antitumor activity of crizotinib observed in both ROS1-

223 Surprisingly, stimulation and antitumor activity of CTL were increased after incubatio

224 Both carriers retained antitumor activity of DAS and could form mixed micelles

225 l characterized, it is not clear whether the antitumor activity of ERbeta can be mobilized in breast

226 L1alpha blockade significantly increased the antitumor activity of erlotinib and cetuximab in vivo.

227 ced IL6 secretion in vitro and increased the antitumor activity of erlotinib in vivo.

228 7 cells, but its role in the development and antitumor activity of IL-17-producing CD8(+) T cells (Tc

229 owever, ICOS stimulation did not augment the antitumor activity of IL-2 expanded T cells.

230 th factor receptor inhibition may complement antitumor activity of immune checkpoint blockade.

231 in target for thalidomide teratogenicity and antitumor activity of immunomodulatory drugs (IMiDs).

232 important metabolic mechanism underlying the antitumor activity of inhibitors of the vacuolar-type AT

233 identify short peptides that potentiate the antitumor activity of interferons.

234 The antitumor activity of KOX/PEGbPHF systemically administe

235 ged lipophilic substituent would enhance the antitumor activity of Met.

236 d drugs in clinical oncology is clear if the antitumor activity of MOv18 IgE in these preclinical exp

237 ld provide a valuable tool to understand the antitumor activity of MSCs and cell cannibalism further,

238 15 superagonist that potently stimulates the antitumor activity of NK cells markedly inhibited acute

239 ety, pharmacokinetics, pharmacodynamics, and antitumor activity of oral BGJ398, a selective FGFR1-3 t

240 Restoration of the antitumor activity of p53 could offer a promising approa

241 cells, in the latter case also enhancing the antitumor activity of paclitaxel while reducing its side

242 However, no study thus far has evaluated the antitumor activity of PD-1-selected TILs in vivo In two

243 We evaluated safety and antitumor activity of pembrolizumab, an anti-PD-1 antibo

244 To enhance the antitumor activity of RG7787, we screened for clinically

245 t profile, pharmacokinetics, and preliminary antitumor activity of rociletinib.

246 in Met-amplified MKN45 cells sensitized the antitumor activity of SAIT301.

247 nnoma allograft was also used to examine the antitumor activity of SFN.

248 I CD20 Abs to induce CDC, and thereby to the antitumor activity of such Abs in the clinic.

249 Therefore, the major component of the antitumor activity of sustained high doses of type I IFN

250 ould mitigate antigen escape and improve the antitumor activity of T cells.

251 umor responses, suggesting that the impaired antitumor activity of the BRAF inhibitor observed in mic

252 The antitumor activity of the combination therapy was CD8 de

253 In this work, we studied the antitumor activity of the IL-15 superagonist receptor-li

254 fect on NK cell infiltration might limit the antitumor activity of the inhibitors.

255 Two clinical trials demonstrated antitumor activity of the long-acting somatostatin analo

256 We assessed the safety and antitumor activity of the programmed cell death protein

257 g a contribution of the immune system to the antitumor activity of these ADCs.

258 factors that likely contribute to the strong antitumor activity of this compound.

259 induced survivin expression and enhanced the antitumor activity of TPM.

260 the uptake, intracellular localization, and antitumor activity of two rhomboidal Pt(II)-based SCCs.

261 macokinetics, pharmacodynamics, and clinical antitumor activity of varlilumab.

262 amide, (R)-16m also displayed marked in vivo antitumor activity on VCaP xenografts and thus it may se

263 anti-PD-1 antibody treatment had additional antitumor activity only when combined with sorafenib and

264 able toxicity profile with early evidence of antitumor activity, particularly in RCC.

265 However, antitumor activity, particularly in the context of progr

266 y studies demonstrated that (19)F-FCP has an antitumor activity profile similar to that of the parent

267 heir contribution to T-cell infiltration and antitumor activity remain unknown.

268 ulations showed that effective, MSU-mediated antitumor activity required coadministration with Mycoba

269 tion of CD4(+) and CD8(+) T cells to CTL and antitumor activity, respectively, was elucidated.

270 and beta-lapachone are combined, synergistic antitumor activity results from sustained NAD(P)H levels

271 Antitumor activity (seven partial responses [six confirm

272 0 mg/kg) in SD rats, and significant in vivo antitumor activity (T/C = 32%, 20 mg/kg, IV) in mice bea

273 35 with systemic anti-PD-1 generates greater antitumor activity than each respective monotherapy.

274 tumor promoting effects of IL-23 has greater antitumor activity than either agent alone.

275 ly, the Taxol((R)) formulation showed higher antitumor activity than the paclitaxel-transferrin formu

276 lay low proliferative responses and impaired antitumor activity that can be partially restored by ant

277 Among the 27 patients who were evaluable for antitumor activity, the overall response rate was 18.5%,

278 uin inhibitors are being evaluated for their antitumor activity, this study refocuses attention on th

279 ses in some patients with cancer, with their antitumor activity tightly correlated with their persist

280 These combined mechanisms imparted potent antitumor activity to 1F5mIgG2a, particularly against th

281 t, compound 14d displayed promising in vitro antitumor activity toward three different prostate cance

282 sing the NCI 60 cell line panel) and in vivo antitumor activity, toxicology, and mouse pharmacokineti

283 ond-generation CAR was essential for optimal antitumor activity, two CD28-based CAR constructs target

284 Enhanced antitumor activity was associated with a unique tumor cy

285 Finally, superior antitumor activity was demonstrated by PEG5K-Fmoc-VE2/DO

286 The antitumor activity was evaluated, showing that treatment

287 basic side chains, but the greatest in vivo antitumor activity was found for compounds containing a

288 IPH4102 antitumor activity was mediated by antibody-dependent ce

289 Relatively modest antitumor activity was observed in multiple xenograft mo

290 Such enhanced DNA damage and antitumor activities were seen in the presence of Rad51

291 ll response and, importantly, the beneficial antitumor activity were largely preserved in NFAT-defici

292 in a mouse syngeneic model demonstrated high antitumor activity which significantly reduced the tumor

293 ouse-specific Dll4 antibodies exerted potent antitumor activity, which relied entirely on targeting D

294 Intriguingly, the tested compounds displayed antitumor activity, while being less toxic against nonca

295 Nivolumab demonstrated antitumor activity with a manageable safety profile acro

296 n this single-group study, idelalisib showed antitumor activity with an acceptable safety profile in

297 dded disaccharide, possesses potent in vitro antitumor activity with an unknown mechanism of function

298 se it exhibited enhanced (>30-fold) in vitro antitumor activity with respect to DCA and increased in

299 d CD4(+) T cells were necessary for enhanced antitumor activity, with elevated numbers of activated C

300 ta indicate that the combination has greater antitumor activity without additional safety concerns ve